54 related articles for article (PubMed ID: 20505139)
1. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
[TBL] [Abstract][Full Text] [Related]
2. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
Nagane M; Shimizu S; Mori E; Kataoka S; Shiokawa Y
Neuro Oncol; 2010 Jul; 12(7):687-700. PubMed ID: 20511188
[TBL] [Abstract][Full Text] [Related]
3. Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
Lee S; Yagita H; Sayers TJ; Celis E
Cancer Immunol Immunother; 2010 Jul; 59(7):1073-81. PubMed ID: 20213120
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.
Weber TG; Osl F; Renner A; Pöschinger T; Galbán S; Rehemtulla A; Scheuer W
Cancer Res; 2014 Apr; 74(7):1913-23. PubMed ID: 24509903
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis.
Isakova AA; Artykov AA; Plotnikova EA; Trunova GV; Khokhlova VА; Pankratov AA; Shuvalova ML; Mazur DV; Antipova NV; Shakhparonov MI; Dolgikh DA; Kirpichnikov MP; Gasparian ME; Yagolovich AV
Int J Biol Macromol; 2024 Jan; 255():128096. PubMed ID: 37972835
[TBL] [Abstract][Full Text] [Related]
6. Amphiphilic Poly(
Yagolovich A; Kuskov A; Kulikov P; Kurbanova L; Bagrov D; Artykov A; Gasparian M; Sizova S; Oleinikov V; Gileva A; Kirpichnikov M; Dolgikh D; Markvicheva E
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575490
[TBL] [Abstract][Full Text] [Related]
7. Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.
Yagolovich AV; Isakova AA; Artykov AA; Vorontsova YV; Mazur DV; Antipova NV; Pavlyukov MS; Shakhparonov MI; Gileva AM; Markvicheva EA; Plotnikova EA; Pankratov AA; Kirpichnikov MP; Gasparian ME; Dolgikh DA
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791610
[TBL] [Abstract][Full Text] [Related]
8. CD11c regulates hematopoietic stem and progenitor cells under stress.
Hou L; Voit RA; Sankaran VG; Springer TA; Yuki K
Blood Adv; 2020 Dec; 4(24):6086-6097. PubMed ID: 33351105
[TBL] [Abstract][Full Text] [Related]
9. High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
Corvigno S; Mezheyeuski A; De La Fuente LM; Westbom-Fremer S; Carlson JW; Fernebro J; Åvall-Lundqvist E; Kannisto P; Hedenfalk I; Malander S; Rolny C; Dahlstrand H; Östman A
Gynecol Oncol; 2020 Dec; 159(3):860-868. PubMed ID: 33032823
[TBL] [Abstract][Full Text] [Related]
10. Protective Microglial Subset in Development, Aging, and Disease: Lessons From Transcriptomic Studies.
Benmamar-Badel A; Owens T; Wlodarczyk A
Front Immunol; 2020; 11():430. PubMed ID: 32318054
[TBL] [Abstract][Full Text] [Related]
11. CD11c
Golinski ML; Demeules M; Derambure C; Riou G; Maho-Vaillant M; Boyer O; Joly P; Calbo S
Front Immunol; 2020; 11():32. PubMed ID: 32158442
[TBL] [Abstract][Full Text] [Related]
12. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Maitre E; Cornet E; Troussard X
Am J Hematol; 2019 Dec; 94(12):1413-1422. PubMed ID: 31591741
[TBL] [Abstract][Full Text] [Related]
13. Neuronal impairment following chronic Toxoplasma gondii infection is aggravated by intestinal nematode challenge in an IFN-γ-dependent manner.
French T; Düsedau HP; Steffen J; Biswas A; Ahmed N; Hartmann S; Schüler T; Schott BH; Dunay IR
J Neuroinflammation; 2019 Jul; 16(1):159. PubMed ID: 31352901
[TBL] [Abstract][Full Text] [Related]
14. What Makes a pDC: Recent Advances in Understanding Plasmacytoid DC Development and Heterogeneity.
Musumeci A; Lutz K; Winheim E; Krug AB
Front Immunol; 2019; 10():1222. PubMed ID: 31191558
[TBL] [Abstract][Full Text] [Related]
15. Structural Immunology of Complement Receptors 3 and 4.
Vorup-Jensen T; Jensen RK
Front Immunol; 2018; 9():2716. PubMed ID: 30534123
[TBL] [Abstract][Full Text] [Related]
16. Inflammation induces two types of inflammatory dendritic cells in inflamed lymph nodes.
Min J; Yang D; Kim M; Haam K; Yoo A; Choi JH; Schraml BU; Kim YS; Kim D; Kang SJ
Exp Mol Med; 2018 Mar; 50(3):e458. PubMed ID: 29546878
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?
Rosales C
Front Physiol; 2018; 9():113. PubMed ID: 29515456
[TBL] [Abstract][Full Text] [Related]
18. Human dendritic cell subsets: an update.
Collin M; Bigley V
Immunology; 2018 May; 154(1):3-20. PubMed ID: 29313948
[TBL] [Abstract][Full Text] [Related]
19. CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival.
Umit EG; Baysal M; Durmus Y; Demir AM
Int J Lab Hematol; 2017 Oct; 39(5):552-556. PubMed ID: 28603911
[TBL] [Abstract][Full Text] [Related]
20. The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes.
Lukácsi S; Nagy-Baló Z; Erdei A; Sándor N; Bajtay Z
Immunol Lett; 2017 Sep; 189():64-72. PubMed ID: 28554712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
